Antagomir to prevent cardiac arrhythmia (2019-069)

IP Status: Provisional Patent Application Filed

Applications

• Therapeutic (alone or in combination) for cardiac arrhythmias
• Research tool to knock-down miR-448 and or upregulate SCN5A
• Cancer therapeutic (for cancers where miR-448 is relevant)

Technology Overview

Arrhythmic cardiomyopathy can cause severe problems including cardiac arrest and death. Unfortunately, many of the therapeutics to treat arrhythmias can actually have pro-arrhythmic side effects. This technology is an antagomir targeting miR-448 (anti-miR-448), a microRNA linked to the downregulation of the sodium channel SCN5A. Relieving the inhibition of miR-448 facilitates the upregulation of SCN5A, which is protective against arrhythmia, while bypassing the potential pro-arhythmic side-effects of existing therapies.

Phase of Development

TRL: 3
In vitro and in vivo testing.

Desired Partnerships

This technology is now available for:

• License
• Sponsored research
• Co-development

Researchers: Sam Dudley, MD, PhD , Professor of Medicine, Cardiovascular Division, Medical School